Positives

• Long COVID patients on the IMC-2 plus Paxlovid combination achieved a 55% greater reduction in fatigue versus IMC-2 alone, with benefits sustained at 120, 305, and 731-day follow-ups PMC.
  
  
• One patient described the Pridgen protocol as "like a switch that eliminated devastating pain," returning them to walking unassisted, driving, and engaging with the world after 5 months Health Rising.
  
  

Negatives

• Patients on the higher-dose regimen experienced more gastrointestinal side effects than those on the lower dose, reducing overall efficacy at higher exposures Frontiers.
  
  
• A patient should note the published case series enrolled only women in the early cohorts, leaving male responder patterns less well characterized Health Rising.
  
  

Hurdles & Side Effects

• Patients seeking IMC-2 outside a trial must convince a clinician to prescribe valacyclovir and celecoxib together off-label, since the fixed-dose product is not yet FDA approved clinicaltrials.gov.
  
  
• A patient adding celecoxib must screen for cardiovascular and GI bleed risk, while valacyclovir requires kidney-function adjustment for long-term daily use Frontiers.